Reimagining Medicine slide image

Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Financial performance Immunology Ophthalmology Conclusions Ophthalmology Neuroscience Global Health Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 79 Investor Relations | Q2 2023 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation